Your shopping cart is currently empty

ICT10336 is a hypoxia-reactive prodrug of the ATR inhibitor AZD6738. It specifically activates under hypoxic conditions in vitro, selectively releasing AZD6738. This action inhibits ATR activation at the T1989 and S428 phosphorylation sites, consequently disrupting HIF1a-mediated adaptation of hypoxic cancer cells and inducing cell death in both 2D and 3D cancer models. ICT10336 is also a metabolic substrate of CYPOR activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | ICT10336 is a hypoxia-reactive prodrug of the ATR inhibitor AZD6738. It specifically activates under hypoxic conditions in vitro, selectively releasing AZD6738. This action inhibits ATR activation at the T1989 and S428 phosphorylation sites, consequently disrupting HIF1a-mediated adaptation of hypoxic cancer cells and inducing cell death in both 2D and 3D cancer models. ICT10336 is also a metabolic substrate of CYPOR activity. |
| Formula | C32H40N10O7S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.